Rep. Lloyd Doggett Buys Johnson & Johnson (NYSE:JNJ) Shares

Representative Lloyd Doggett (Democratic-Texas) recently bought shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on April 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on March 10th.

Representative Lloyd Doggett also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 3/26/2026.
• Purchased $1,001 – $15,000 in shares of PPG Industries (NYSE:PPG) on 3/12/2026.
• Purchased $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 3/10/2026.
• Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 2/17/2026.

Johnson & Johnson Price Performance

Shares of JNJ stock traded up $0.96 during trading hours on Thursday, hitting $242.26. The stock had a trading volume of 1,092,325 shares, compared to its average volume of 8,603,774. Johnson & Johnson has a one year low of $145.13 and a one year high of $251.71. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The stock’s 50-day moving average price is $240.79 and its two-hundred day moving average price is $214.35. The stock has a market capitalization of $583.52 billion, a price-to-earnings ratio of 21.94, a PEG ratio of 2.41 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion for the quarter. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 1,322 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at approximately $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. The trade was a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 30,142 shares of company stock valued at $7,360,528 in the last quarter. 0.16% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on JNJ shares. Morgan Stanley set a $253.00 price objective on Johnson & Johnson in a research note on Wednesday, March 18th. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a research note on Monday, January 5th. Daiwa Securities Group boosted their price objective on Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research note on Thursday, January 29th. Finally, Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a research note on Friday, January 23rd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $237.57.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Citigroup raised its price target to $285 and kept a Buy rating, citing improved visibility in the medical‑technology group and upside into earnings — a materially bullish signal for investor positioning. Citigroup Forecasts Strong Price Appreciation for Johnson & Johnson (NYSE:JNJ) Stock
• Positive Sentiment: Guggenheim raised its price target modestly to $244 and maintained a Buy rating, reinforcing the consensus analyst upgrade theme that’s supporting JNJ’s near‑term move. Johnson & Johnson (NYSE:JNJ) Stock Price Expected to Rise, Guggenheim Analyst Says
• Positive Sentiment: TD Cowen (Josh Jennings) and other firms reiterated/initiated Buy ratings (TD Cowen price target ~$250), adding fresh broker demand and research flow ahead of Q1 results. Johnson & Johnson: Diversified Growth, Robust Pipeline, and Attractive Risk‑Reward Support Buy Rating
• Positive Sentiment: Media outlets including Barron’s and other buy‑side coverage are encouraging accumulation “ahead of earnings,” which can amplify momentum as investors rotate into perceived defensive, high‑quality healthcare names. Buy Johnson & Johnson Ahead of Earnings. The Stock’s Run-Up Isn’t Over.
• Positive Sentiment: Product development: J&J launched VARIPULSE Pro in Europe (CE mark) — a next‑gen pulsed field ablation catheter that could boost the electrophysiology franchise if commercial uptake meets expectations. J&J advances PFA portfolio with Varipulse Pro launch in Europe
• Neutral Sentiment: Market commentary notes JNJ “increases yet falls behind market,” meaning the stock is up but lagging broader indices — a reminder that macro/sector moves can limit outperformance even with company‑specific positives. Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to Know
• Neutral Sentiment: Other trade and index flow notes (S&P 500 trends, inclusion/visibility) and stock‑screen features are being cited by outlets highlighting JNJ as a low‑volatility blue‑chip idea — supportive for steady demand but not an immediate earnings catalyst. Johnson & Johnson (NYSE:JNJ) Gains Visibility As S&P 500 Today Trends Shift

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Blueline Advisors LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $25,000. Cresta Advisors Ltd. purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $26,000. Abich Financial Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the third quarter valued at approximately $26,000. DecisionPoint Financial LLC boosted its position in shares of Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after buying an additional 75 shares during the period. Finally, Bay Harbor Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 49.0% in the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after purchasing an additional 49 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

About Representative Doggett

Lloyd Doggett (Democratic Party) is a member of the U.S. House, representing Texas’ 37th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Doggett (Democratic Party) is running for re-election to the U.S. House to represent Texas’ 37th Congressional District. He declared candidacy for the 2026 election.

Lloyd Doggett was born in Austin, Texas. Doggett graduated from Austin High School in 1964. He earned a B.A. from the University of Texas at Austin in 1967 and a J.D. from the University of Texas in 1970. Doggett’s career experience includes working as an adjunct professor with the University of Texas School of Law. In the 116th Congress, Doggett served on the House Ways & Means Committee, and he co-founded the House Prescription Drug Taskforce.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.